Seminars in Nuclear Medicine
Volume 36, Issue 3 , Pages 228-247 , July 2006

Imaging of Neuroendocrine Tumors

  • Vittoria Rufini, MD

      Affiliations

    • Department of Nuclear Medicine, Università Cattolica del Sacro Cuore, Rome, Italy
    • Corresponding Author InformationAddress reprint requests to Vittoria Rufini, MD, Istituto di Medicina Nucleare, Policlinico Gemelli, Largo A. Gemelli 8, 00168 Roma, Italy
    • ,
  • Maria Lucia Calcagni, MD

      Affiliations

    • Department of Nuclear Medicine, Università Cattolica del Sacro Cuore, Rome, Italy
    • ,
  • Richard P. Baum, MD

      Affiliations

    • Department of Nuclear Medicine/PET Center, Zentralklinik Bad Berka, Bad Berka, Germany

References 

  1. Kaltsas GA , Besser GM , Grossman AB . The diagnosis and medical management of advanced neuroendocrine tumors . Endocr Rev . 2004;25:458–511
  2. Solcia E , Kloeppel G , Sobin LH . Histological typing of endocrine tumors . (ed 2). Berlin Heidelberg: Springer-Verlag; 2000;
  3. Wieland DM , Wu JL , Brown LE , et al.   Radiolabeled adrenergic neuron blocking agents (adrenomedullary imaging with 131I-iodobenzylguanidine) . J Nucl Med . 1980;21:349–353
  4. McEwan AJ , Shapiro B , Sisson JC , et al.   Radioiodobenzylguanidine for the scintigraphic location and therapy of adrenergic tumors . Semin Nucl Med . 1985;5:132–153
  5. Hor G , Maul FD , Kornhuber B , et al.   Outcome of [131I]metaiodobenzylguanidine therapy of neuroblastoma (seven years after) . J Nucl Biol Med . 1991;35:207–215
  6. Shapiro B , Sisson JC , Shulkin BL . The current status of Meta-Iodobenzylguanidine and related agents for the diagnosis of neuro-endocrine tumors . Q J Nucl Med . 1995;39(suppl. 1 to no. 4):3–8
  7. Shulkin BL , Shapiro B . Current concepts on the diagnostic use of MIBG in children . J Nucl Med . 1998;39:679–688
  8. Hoefnagel CA , Lewington VJ . MIBG therapy . In:  Ell PJ ,  Gambhir SS editor. Nuclear Medicine in Clinical Diagnosis and Treatment . vol 1: Edinburgh: Churchill Livingstone; 2004;p. 445–457
  9. Troncone L , Rufini V . MIBG in diagnosis of neuroendocrine tumors . In:  Ell PJ ,  Gambhir SS editor. Nuclear Medicine in Clinical Diagnosis and Treatment . vol 1: Edinburgh: Churchill Livingstone; 2004;p. 83–95
  10. Kwekkeboom DJ , Krenning EP . Somatostatin receptor imaging . Semin Nucl Med . 2002;32:84–91
  11. Van Den Bossche B , Van de Wiele C . Receptor imaging in oncology by means of nuclear medicine (current status) . J Clin Oncol . 2004;22:3593–3607
  12. Eriksson B , Orlefors H , Oberg K , et al.   Developments in PET for the detection of endocrine tumours . Best Pract Res Clin Endocrinol Metab . 2005;19:311–324
  13. Hofmann M , Maecke H , Börner AR , et al.   Biokinetics and imaging with the somatostatin receptor PET radioligand Ga-68 DOTATOC (preliminary data) . Eur J Nucl Med . 2001;28:1751–1757
  14. Baum RP , Hofmann M . Nuklearmedizinische Diagnostik neuroendokriner Tumoren . Onkologe . 2004;10:598–610
  15. Wafelman AR , Hoefnagel CA , Maes RAA , et al.   Radioiodinated metaiodobenzylguanidine (a review of its biodistribution and pharmacokinetics, drug interaction, cytotoxicity and dosimetry) . Eur J Nucl Med . 1994;21:545–559
  16. Kolby L , Bernhardt P , Levin-Jakobsen AM , et al.   Uptake of meta-iodobenzylguanidine in neuroendocrine tumors is mediated by vesicular monoamine transporters . Br J Cancer . 2003;89:1383–1388
  17. Bombardieri E , Aktolun C , Baum RP , et al.   131I/123I-Metaiodobenzylguanidine (MIBG) scintigraphy (procedure guidelines for tumor imaging) . Eur J Nucl Med Mol Imaging . 2003;30:BP132–BP139
  18. Eisenhofer G , Pacak K , Goldstein DS , et al.   123I-MIBG scintigraphy of catecholamine systems (impediments to applications in clinical medicine) . Eur J Nucl Med . 2000;27:611–612 letter
  19. Vaidyanathan G , Zalutsky MR . No-carrier-added synthesis of meta-[131I]iodobenzylguanidine . Appl Radiat Isot . 1993;44:621–628
  20. Mairs RJ , Cunningham SH , Russel J , et al.   No-carrier-added iodine-131-MIBG. Evaluation of a therapeutic preparation . J Nucl Med . 1995;36:1088–1095
  21. Owens J , Bolster AA , Prosser JE , et al.   No-carrier-added 123I-MIBG (an initial clinical study in patients with phaeochromocytoma) . Nucl Med Commun . 2000;21:437–440
  22. Rufini V , Fisher GA , Shulkin BL , et al.   Iodine-123-MIBG imaging of neuroblastoma (utility of SPECT and delayed imaging) . J Nucl Med . 1996;37:1464–1468
  23. Schillaci O . Functional-anatomical image fusion in neuroendocrine tumors . Cancer Biother Radiopharm . 2004;19:129–134
  24. Shulkin BL , Sisson JC , Koral KE , et al.   Conjugate view gammacamera method for estimating tumor uptake of iodine-131 meta-iodobenzylguanidine . J Nucl Med . 1988;29:542–548
  25. Bonnin F , Lumbroso J , Tenebaum F , et al.   Refining interpretation of MIBG scans in children . J Nucl Med . 1994;35:803–810
  26. Okuyama C , Ushijima Y , Kubota T , et al.   123I-Metaiodobenzylguanidine uptake in the nape of the neck of children (likely visualization of brown adipose tissue) . J Nucl Med . 2003;44:1421–1425
  27. Gelfand MJ . 123I-MIBG uptake in the neck and shoulders of a neuroblastoma patient (damage to sympathetic innervation blocks uptake in brown adipose tissue) . Pediatr Radiol . 2004;34:577–579
  28. Boersma HH , Wensing JW , Kho TL , et al.   Transient enhanced uptake of 123I- metaiodobenzylguanidine in the contralateral adrenal region after resection of an adrenal pheochromocytoma . N Engl J Med . 2000;342:1450–1451
  29. Leung A , Shapiro B , Hattner R , et al.   The specificity of radioiodinated MIBG for neural crest tumors in childhood . J Nucl Med . 1997;38:1352–1357
  30. Reubi JC , Schar JC , Waser B , et al.   Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use . Eur J Nucl Med . 2000;27:273–282
  31. Reubi JC , Waser B . Concomitant expression of several peptide receptors in neuroendocrine tumours (molecular basis for in vivo multireceptor tumour targeting) . Eur J Nucl Med Mol Imaging . 2003;30:781–793
  32. Reubi JC . Peptide receptors as molecular targets for cancer diagnosis and therapy . Endocr Rev . 2003;24:389–427
  33. McCarthy KE , Wolteeing EA , Anthony LB . In situ radiotherapy with 111In-pentetreotide. State of the art and perspectives . Q J Nucl Med . 2000;44:88–95
  34. Valkema R , De Jong M , Bakker WH , et al.   Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide (the Rotterdam experience) . Semin Nucl Med . 2002;32:110–122
  35. Bombardieri E , Aktolun C , Baum RP , et al.   111In-pentetreotide scintigraphy (procedure guidelines for tumor imaging) . Eur J Nucl Med Mol Imaging . 2003;30:BP140–BP147
  36. Maecke HR , Behe M . New octreotide derivatives labelled with technetium-99m . (abstract) J Nucl Med . 1996;37:1144
  37. Rösch F , Herzog H , Stolz B , et al.   Uptake kinetics of the somatostatin receptor ligand [86Y]DOTA-DPhe1-Tyr3-octreotide ([86Y]SMT487) using positron emission tomography . Eur J Nucl Med . 1999;26:358–366
  38. Lewis JS , Lewis MR , Srinivasan A . Comparison of four 64Cu-labeled somatostatin analogues in vitro and in a tumor-bearing rat model (Evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy) . J Med Chem . 1999;42:1341–1347
  39. Kwekkeboom DJ , Kooij PP , Bakker WH , et al.   111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients (biodistribution, kinetics, organ and tumor uptake) . J Nucl Med . 1999;40:762–767
  40. Otte A , Herrmann R , Heppeler A , et al.   Yttrium-90 DOTATOC (first clinical results) . Eur J Nucl Med . 1999;26:1439–1447
  41. Waldherr C , Pless M , Maecke HR , et al.   Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC . J Nucl Med . 2002;43:610–616
  42. Paganelli G , Zoboli S , Cremonesi M , et al.   Receptor-mediated radiotherapy with 90Y-DOTA-d-Phe1-Tyr3-octreotide . Eur J Nucl Med . 2001;28:426–434
  43. Pashankar FD , O’Dorisio MS , Menda Y . MIBG and somatostatin receptor analogs in children (current concepts on diagnostic and therapeutic use) . J Nucl Med . 2005;46:55S–61S
  44. Kaltsas GA , Papadogias D , Makras P , et al.   Treatment of advanced neuroendocrine tumours with radiolabeled somatostatin analogues . Endocr Relat Cancer . 2005;12:683–699
  45. Kwekkeboom D , Krenning EP , de Jong M . Peptide receptor imaging and therapy . J Nucl Med . 2000;41:1704–1713
  46. Ginj M , Chen J , Walter MA , et al.   Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy . Clin Cancer Res . 2005;11:1136–1145
  47. Wild D , Mäcke HR , Waser B , et al.   68Ga-DOTANOC (a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5) . Eur J Nucl Med Mol Imaging . 2005;32:724
  48. Wild D , Schmitt JS , Ginj M , et al.   DOTA-NOC, a high-affinity ligand of somatostatin receptors subtypes 2, 3 and 5 for labelling with various radiometals . Eur J Nucl Med Mol Imaging . 2003;30:1338–1347
  49. Baum RP , Niesen A , Leonhardi J , et al.   Receptor PET/CT imaging of neuroendocrine tumors using the Ga-68 labelled, high affinity somatostatin analogue DOTA-1-Nal3-octreotide (DOTA-NOC) (clinical results in 327 patients) . Eur J Nucl Med Mol Imaging . 2005;32:S54; (abstr)
  50. Virgolini I , Traub T , Leimer M , et al.   New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy . Q J Nucl Med . 2000;44:50–58
  51. Reubi JC , Mäcke HR , Krenning EP . Candidates for peptide receptor radiotherapy today and in the future . J Nucl Med . 2005;46:67S–75S
  52. Chiti A , Briganti V , Fanti S , et al.   Results and potential in neuroendocrine gastro-entero-pancreatic tumors . Q J Nucl Med . 2000;44:42–49
  53. Briganti V , Matteini M , Ferri P , et al.   Octreoscan SPET evaluation in the diagnosis of pancreas neuroendocrine tumors . Cancer Biother Radiopharm . 2001;16:512–524
  54. Oberg K , Kvols L , Caplin M , et al.   Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system . Ann Oncol . 2004;15:966–973
  55. Oberg K , Eriksson B . Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours . Best Pract Res Clin Endocrinol Metab . 2005;19:265–276
  56. Warner RP , O’Dorisio T . Radiolabeled peptides in diagnosis and tumor imaging (clinical overview) . Semin Nucl Med . 2002;32:79–83
  57. Virgolini I , Raderer M , Kurtaran A , et al.   Vasoactive intestinal peptide (VIP) receptor imaging in the localization of intestinal adenocarcinomas and endocrine tumors . N Engl J Med . 1994;331:1116–1121
  58. Reubi JC . Somatostatin and other peptides receptors as tools for tumor diagnosis and treatment . Neuroendocrinology . 2004;80(suppl 1):51–56
  59. Breeman WA , De Jong M , Bernard BF , et al.   Pre-clinical evaluation of [(111)In-DTPA-Pro(1),Tyr(4)]bombesin, a new radioligand for bombesin-receptor scintigraphy . Int J Cancer . 1999;83:657–663
  60. Van de Wiele C , Dumont F , Vanden Broecke R , et al.   Technetium 99m RP527, a GRP analogue for visualization of GRP receptor-expressing malignancies (a feasibility study) . Eur J Nucl Med . 2000;27:1694–1699
  61. Hofmann M , Gali H , Smith CJ , et al.   Novel series of 111In- labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells . J Nuc Med . 2003;44:823–831
  62. Scopinaro F , De Vincentis G , Varvarigou AD , et al.   99mTc-bombesin detects prostate cancer and invasion of pelvic lymph nodes . Eur J Nucl Med Mol Imaging . 2003;30:1378–1382
  63. Nock B , Nikolopoulou A , Chiotellis E , et al.   [99mTc]demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging . Eur J Nucl Med . 2003;30:247–258
  64. Reubi JC , Korner M , Waser B , et al.   High expression of peptide receptors as a novel target in gastrointestinal stromal tumours . Eur J Nucl Med Mol Imaging . 2004;31:803–810
  65. Schuhmacher J , Zhang H , Doll J , et al.   GRP receptor-targeted PET of a rat pancreas carcinoma xernograft in nude mice with a 68Ga-labeled bombesin (6-14) analog . J Nucl Med . 2005;46:691–699
  66. Kwekkeboom DJ , Bakker WH , Kooij PP , et al.   Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma . Eur J Nucl Med . 2000;27:1312–1317
  67. Behr TM , Behe MP . Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor expressing malignancies . Semin Nucl Med . 2002;32:97–109
  68. Bernard BF , Béhé M , Breeman WAP , et al.   Preclinical evaluation of minigastrin analogs for CCK-B receptor targeting . (abstr) Cancer Biother Radiopharm . 2003;18:281
  69. Béhé M , Behr TM , Schmalor W , et al.   Indium-111 labeled GLP-1 for in vivo diagnostic of insulinomas . (abstr) J Nucl Med . 2002;43(suppl):92P
  70. Gotthardt M , Fischer M , Naeher I , et al.   Use of the incretin hormone glucagon-like peptide-I (GLP-I) for the detection of insulinomas (initial experimental results) . Eur J Nucl Med Mol Imaging . 2002;29:597–606
  71. Reubi JC , Gugger M , Waser B , et al.   Y1-mediated effect of neuropeptide Y in cancer (breast carcinomas as targets) . Cancere Res . 2001;61:4636–4641
  72. Körner M , Waser B , Reubi JC . High expression of neuropeptide Y receptors in tumors of the human adrenal gland and extraadrenal paraganglia . Clin Cancer Res . 2004;10:8426–8433
  73. Buchegger F , Bonvin F , Kosinski A , et al.   Radiolabeled neurotensin analog, 99mTc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients . J Nucl Med . 2003;44:1649–1654
  74. van Hagen PM , Breeman WA , Reubi JC , et al.   Visualization of the thymus by substance P receptor scintigraphy in man . Eur J Nucl Med . 1996;23:1508–1513
  75. Schumacher T , Eichhorn K , Hofer S , et al.   Diffusible brachytherapy (DBT) with radiolabeled substance P in high grade gliomas (first observation) . Eur J Nucl Med . 2001;28: (abstr)
  76. Hessenius C , Bäder M , Meinhold H , et al.   Vasoactive intestinal peptide receptor scintigraphy in patients with pancreatic adenocarcinomas or neuroendocrine tumors . Eur J Nucl Med . 2000;27:1684–1693
  77. Reske SN , Kotzerke J . FDG-PET for clinical use. Results of the 3rd German interdisciplinary consensus conference “Onko-PET III”, 21 July and 19 September 2000 . Eur J Nucl Med . 2001;28:1707–1723
  78. Bombardieri E , Aktolun C , Baum RP , et al.   FDG-PET (Procedure guidelines for tumour imaging) . Eur J Nucl Med . 2003;30:BP115–BP124
  79. Adams S , Baum R , Rink T , et al.   Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours . Eur J Nucl Med . 1998;25:79–83
  80. Pasquali C , Rubello D , Sperti C , et al.   Neuroendocrine tumors imaging (can 18F-Fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behaviour?) . World J Surg . 1998;22:588–592
  81. Eriksson B , Bergstrom M , Orlefors H , et al.   Use of PET in neuroendrocrine tumors. In vivo applications and in vitro studies . Q J Nucl Med . 2000;44:68–76
  82. Eriksson B , Bergstrom M , Sundin A , et al.   The role of PET in localization of neuroendocrine and adrenocortical tumors . Ann N Y Acad Sci . 2002;970:159–169
  83. Schwaiger M , Kalff V , Rosenspire K , et al.   Noninvasive evaluation of sympathetic nervous system in human heart by positron emission tomography . Circulation . 1990;82:457–464
  84. Shulkin BL , Wieland DM , Schwaiger M , et al.   PET scanning with hydroxyephedrine (an approach to the localization of pheochromocytoma) . J Nucl Med . 1992;33:1125–1131
  85. De Grado TR , Hutchins GD , Toorongian SA , et al.   Myocardial kinetics of 11C-metahydroxyephedrine (retention mechanisms and effects of norepinephrine) . J Nucl Med . 1993;34:1287–1293
  86. Shulkin BL , Wieland DM , Baro ME , et al.   PET hydroxyephedrine imaging of neuroblastoma . J Nucl Med . 1996;37:16–21
  87. Eisenhofer G . The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines . Pharmacol Ther . 2001;91:35–62
  88. Mamede M , Carrasquillo JA , Chen CC , et al.   Discordant localization of 2-[18F]-fluoro-2-deoxy-D-glucose in 6-[18F]-fluorodopamine- and [123I]-metaiodobenzylguanidine-negative metastatic pheochromocytoma sites . Nucl Med Commun . 2006;27:31–36
  89. Pacak K , Goldstein DS , Doppman JL , et al.   A “pheo” lurks (novel approaches for locating occult pheochromocytoma) . J Clin Endocrinol Metab . 2001;86:3641–3646
  90. Ilias I , Yu J , Carrasquillo JA , et al.   Superiority of 6-[18F]-Fluorodopamine positron emission tomography versus [131I]-Metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma . J Clin Endocrinol Metab . 2003;88:4083–4087
  91. Hoegerle S , Schneider B , Kraft A , et al.   Imaging of a metastatic gastrointestinal carcinoid by F-18-DOPA positron emission tomography . Nuklearmedizin . 1999;38:127–130
  92. Ahlstrom H , Eriksson B , Bergstrom M , et al.   Pancreatic neuroendocrine tumors (diagnosis with PET) . Radiology . 1995;195:333–337
  93. Bergstrom M , Eriksson B , Oberg K , et al.   In vivo demonstration of enzyme activity in endocrine pancreatic tumors (decarboxylation of carbon-11-DOPA to carbon-11-dopamine) . J Nucl Med . 1996;37:32–37
  94. Hoegerle S , Altehoefer C , Ghanem N , et al.   18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels . Eur J Nucl Med . 2001;28:64–71
  95. Hoegerle S , Nitzsche E , Altehoefer C , et al.   Pheochromocytomas (detection with 18F DOPA whole-body PET-initial results) . Radiology . 2003;222:507–512
  96. Orlefors H , Sundin A , Ahlstrom H , et al.   Positron emission tomography with 5-hydroxytryptophan in neuroendocrine tumors . J Clin Oncol . 1998;16:2534–2541
  97. Sundin A , Eriksson B , Bergstrom M , et al.   Demonstration of [11C] 5-hydroxy-L-tryptophan uptake and decarboxylation in carcinoids tumors by specific positioning labelling in positron emission tomography . Nucl Med Biol . 2000;27:33–41
  98. Orlefors H , Sundin A , Garske U , et al.   Whole-body 11C-5-Hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors (comparison with somatostatin receptor scintigraphy and computed tomography) . J Clin Endocrinol Metab . 2005;90:3392–3400
  99. Maecke HR , Hofmann M , Haberkorn U . 68(Ga)-labeled peptides in tumor imaging . J Nucl Med . 2005;46(suppl 1):172S–178S
  100. Baum RP , Schmücking M , Niesen A , et al.   Receptor-PET/CT of neuroendocrine tumors using the gallium-68 labelled somatostatin analog DOTA-NOC (first clinical results) . Eur Radiol . 2005;15(suppl 1):C-0409; (abstr)
  101. Henze M , Schuhmacher J , Hipp P , et al.   PET imaging of somatostatin receptors using [68Ga]DOTA-D-Phe1-Tyr3-Octreotide (first results in patients with meningiomas) . Eur J Nucl Med . 2001;42:1053–1056
  102. Anderson CJ , Dehdashti F , Cutler PD , et al.   64Cu-TETA-Octreotide as a PET imaging agent for patients with neuroendocrine tumors . J Nucl Med . 2001;42:213–221
  103. Wester HJ , Schottelius M , Scheidhauer K . PET imaging of somatostatin receptors (design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue octreotide) . Eur J Nucl Med Mol Imaging . 2003;30:117–122
  104. Mantero F , Terzolo M , Arnaldi G , et al.  Study group on adrenal tumors of the Italian Society of Endocrinology   A survey on adrenal incidentaloma in Italy . J Clin Endocrinol Metab . 2000;85:637–644
  105. Klingler HC , Klingler PJ , Martin JK , et al.   Pheochromocytoma. Urology . 2001;57:1025–1032
  106. Pacak K , Linehan WM , Eisenhofer G , et al.   Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma . Ann Intern Med . 2001;134:315–329
  107. Pomares FJ , Canas R , Rodriguez JM , et al.   Differences between sporadic and multiple endocrine neoplasia type 2A pheochromocytoma . Clin Endocrinol . 1998;48:195–200
  108. Shapiro B , Copp JE , Sisson JC , et al.   131-Iodine-metaiodobenzylguanidine for the locating of suspected pheochromocytoma (experience in 400 cases) . J Nucl Med . 1985;26:576–585
  109. Troncone L , Rufini V , Montemaggi P , et al.   The diagnostic and therapeutic utility of radioiodinated metaiodobenzylguanidine (MIBG) (5 years of experience) . Eur J Nucl Med . 1990;16:325–335
  110. Sisson JC , Shulkin BL . Nuclear medicine imaging of pheochromocytoma and neuroblastoma . Q J Nucl Med . 1999;43:217–223
  111. Shapiro B , Gross MD , Shulkin B . Radioisotope diagnosis and therapy of malignant pheochromocytoma . Trends Endocrinol Metab . 2001;12:469–475
  112. Taieb D , Sebag F , Hubbard JG , et al.   Does iodine-131-meta-iodobenzylguanidine (MIBG) scintigraphy have an impact on the management of sporadic and familial pheochromocytoma? . Clin Endocrinol . 2004;61:102–108
  113. Maurea S , Cuocolo A , Reynolds JC , et al.   Iodine-131-metaiodobenzylguanidine scintigraphy in preoperative and post-operative evaluation of paragangliomas (comparison with CT and MRI) . J Nucl Med . 1993;34:173–179
  114. Jalil ND , Pattou FN , Combemale F , et al.  French Association of Surgery (AFC)  French Association of Endocrine Surgeons (AFCE)   Effectiveness and limits of preoperative imaging studies for the localisation of pheochromocytomas and paragangliomas (a review of 282 cases) . Eur J Surg . 1998;164:23–28
  115. Berglund AS , Hulthen UL , Manhem P , et al.   Metaiodobenzylguanidine (MIBG) scintigraphy and computed tomography (CT) in clinical practice. Primary and secondary evaluation for localization of pheochromocytomas . J Intern Med . 2001;249:247–251
  116. d’Herbomez M , Gouze V , Huglo D , et al.   Chromogranin A assay and 131I-MIBG scintigraphy for diagnosis and follow-up of pheochromocytoma . J Nucl Med . 2001;42:993–997
  117. Guller U , Turek J , Eubanks S , et al.   Detecting pheochromocytoma (defining the most sensitive test) . Ann Surg . 2006;243:102–107
  118. Furuta N , Kiyota H , Yoshigoe F , et al.   Diagnosis of pheochromocytoma using [123I]- compared with [131I]-metaiodobenzylguanidine scintigraphy . Int J Urol . 1999;6:119–124
  119. Adams S , Acker P , Lorenz M , et al.   Radioisotope-guided surgery in patients with pheochromocytoma and recurrent medullary thyroid carcinoma (a comparison of preoperative and intraoperative tumor localization with histopathologic findings) . Cancer . 2001;92:263–270
  120. Baum RP , Sandrucci S , Adams S . Radioguided Surgery of Neuroendocrine tumors . In:  Mariani G ,  Giordano AE ,  Strauss HW editor. Radioguided Surgery (A Comprehensive Team Approach) . New York: Springer Verlag; 2006; (in press)
  121. van der Harst E , De Herder WW , Bruining HA , et al.   [123I]Metaiodobenzylguanidine and [111In]Octreotide uptake in benign and malignant pheochromocytomas . J Clin Endocrinol Metab . 2001;86:685–693
  122. Troncone L , Rufini V . Nuclear medicine therapy of pheochromocytoma and neuroblastoma . Q J Nucl Med . 1999;43:344–355
  123. Kwekkeboom DJ , van Urk H , Pauw BKH , et al.   Octreotide scintigraphy for detection of paragangliomas . J Nucl Med . 1993;34:873–878
  124. van Gelder T , Verhoeven GT , de Jong P , et al.   Dopamine-producing paraganglioma not visualized by iodine-123-MIBG scintigraphy . J Nucl Med . 1995;36:620–622
  125. Yun M , Kim W , Alnafisi N , et al.   18F-FDG-PET in characterizing adrenal lesions detected on CT or MRI . J Nucl Med . 2001;42:1795–1799
  126. Rubello D , Rufini V , Casara D , et al.   Clinical role of positron emission tomography (PET) in endocrine tumours . Panminerva Med . 2002;44:185–196
  127. Shulkin BL , Thompson NW , Shapiro B , et al.   Pheochromocytomas (imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET) . Radiology . 1999;212:35–41
  128. Ilias I , Pacak K . Diagnosis and management of tumors of the adrenal medulla . Horm Metab Res . 2005;37:717–721
  129. Pacak K , Eisenhofer G , Carrasquillo JA , et al.   6-[18F]-fluorodopamine positron emission tomography (PET) scanning for diagnostic localization of pheochromocytoma . Hypertension . 2001;38:6–8
  130. Brink J , Hoegerle S , Klisch J , et al.   Imaging of pheochromocytoma and paraganglioma . Familial Cancer . 2005;4:61–68
  131. Mangner WM . In search of pheochromocytomas . J Clin Endocrinol Metab . 2003;88:4080–4082
  132. Berry CL . Imaging of pheochromocytoma in 2 dogs using p-[18F]fluorobenzylguanidine . Vet Radiol Ultrasound . 2002;43:183–186
  133. Boubaker A , Bischof Delaloye A . Nuclear medicine procedures and neuroblastoma in childhood. Their value in the diagnosis, staging and assessment of response to therapy . Q J Nucl Med . 2003;47:31–40
  134. Katzenstein HM , Cohn SL , Shore RM , et al.   Scintigraphic response by 123I-metaiodobenzylguanidine scan correlates with event-free survival in high-risk neuroblastoma . J Clin Oncol . 2004;22:3909–3915
  135. Olivier P , Colarinha P , Fettich J , et al.   Guidelines for radioiodinated MIBG scintigraphy in children . Eur J Nucl Med Mol Imaging . 2003;30:BP45–BP50
  136. Schilling FH , Bihl H , Jacobsson H , et al.   Combined 111In-Pentetreotide scintigraphy and 123I-mIBG scintigraphy in neuroblastoma provides prognostic information . Med Pediatr Oncol . 2000;35:688–691
  137. Kushner BH . Neuroblastoma (a disease requiring a multitude of imaging studies) . J Nucl Med . 2004;45:1172–1188
  138. Briganti V , Sestini R , Orlando C , et al.   Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor type 2 gene expression in neuroblastoma tumors . Clin Cancer Res . 1997;3:2385–2391
  139. Kushner BH , Yeung HW , Larson SM , et al.   Extending positron emission tomography scan utility to high-risk neuroblastoma (fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients) . J Clin Oncol . 2001;19:3397–3405
  140. Oberg K . Neuroendocrine gastrointestinal tumors . Ann Oncol . 1996;7:453–463
  141. Oberg K . State of the art and future prospects in the management of neuroendocrine tumors . Q J Nucl Med . 2000;44:3–12
  142. Rindi G , Capella C , Solcia E . Introduction to a revised clinicopathological classification of neuroendocrine tumors of the gastroenteropancreatic tract . Q J Nucl Med . 2000;44:13–21
  143. Seregni E , Ferrari L , Stivanello M , et al.   Laboratory tests for neuroendocrine tumours . Q J Nucl Med . 2000;44:22–41
  144. Caplin ME , Buscombe JR , Hilson AJ , et al.   Carcinoid tumor . Lancet . 1998;352:799–805
  145. Hiramoto JS , Feldstein VA , LaBerge JM , et al.   Intraoperative ultrasound and preoperative localization detects all occult insulinomas . Arch Surg . 2001;136:1020–1026
  146. Shin HJ , Lahoti S , Sneige N . Endoscopic ultrasound-guided fine-needle aspiration in 179 cases (the M.D. Anderson Cancer Center experience) . Cancer . 2002;96:174–180
  147. Krenning EP , Kwekkeboom DJ , Bakker WH , et al.   Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide (the Rotterdam experience with more than 1,000 patients) . Eur J Nucl Med . 1993;20:716–731
  148. Schillaci O , Spanu A , Scopinaro F , et al.   Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors . J Nucl Med . 2003;44:359–368
  149. Jensen RT . Carcinoid and pancreatic endocrine tumors (recent advances in molecular pathogenesis, localization and treatment) . Curr Opin Oncol . 2000;12:368–377
  150. Adams S , Baum RP , Hertel A , et al.   Intraoperative gamma probe detection of neuroendocrine tumors . J Nucl Med . 1998;39:1155–1160
  151. Benjegard SA , Forssell-Aronsson E , Wangberg B , et al.   Intraoperative tumor detection using 111In-DTPA-D-Phe1-octreotide and a scintillator detector . Eur J Nucl Med . 2001;28:1456–1462
  152. Lebtahi R , Cadiot G , Sarda L , et al.   Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors . J Nucl Med . 1997;38:853–858
  153. Chiti A , Fanti S , Savelli G , et al.   Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumors . Eur J Nucl Med . 1998;25:1396–1403
  154. Savelli G , Lucignani G , Seregni E , et al.   Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero-pancreatic (GEP) neuroendocrine tumours . Nucl Med Commun . 2004;25:445–449
  155. Termanini B , Gibril F , Reynolds JC , et al.   Value of somatostatin receptor scintigraphy (a prospective study in gastrinoma of its effect on clinical management) . Gastroenterology . 1997;112:335–347
  156. Bombardieri E , Seregni E , Villano C , et al.   Position of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors . Q J Nucl Med . 2004;48:150–163
  157. Schillaci O . Hybrid SPET/CT (a new era for SPET imaging?) . Eur J Nucl Med Mol Imaging . 2005;32:521–524
  158. Krausz Y , Keidar Z , Kogan I , et al.   SPECT/CT hybrid imaging with 111In-pentetreotide in assessmentt of neuroendocrine tumours . Clin Endocrinol . 2003;59:565–573
  159. Blum J , Handmaker H , Lister-James J , et al.   A multicenter trial with a somatostatin analog (99m)Tc depreotide in the evaluation of solitary pulmonary nodules . Chest . 2000;117:1232–1238
  160. Lebtahi R , Le Cloirec J , Houzard C , et al.   Detection of neuroendocrine tumors (99mTc-P829 scintigraphy compared with 111In-pentetreotide scintigraphy) . J Nucl Med . 2002;43:889–895
  161. Baum RP , Schmuecking M , Fischer S , et al.   Somatostatin receptor scintigraphy using Tc-99m EDDA-TRYCINE-HYNIC-TOC (clinical results in different tumour types and comparison with In-111 DOTATOC during Y-90 DOTATOC radioreceptor therapy) . Eur J Nucl Med Mol Imaging . 2002;29:S100; (abstr)
  162. Gabriel M , Muehllechner P , Decristoforo C , et al.   99mTc-EDDA/HYNIC-Tyr(3)-octreotide for staging and follow-up of patients with neuroendocrine gastro-entero-pancreatic tumors . Q J Nucl Med . 2005;49:237–244
  163. Taal BG , Hoefnagel CA , Valdés Olmos RA , et al.   Combined diagnostic imaging with 131I-metaiodobenzylguanidine and 111In-pentetreotide in carcinoid tumours . Eur J Cancer . 1996;32A:1924–1932
  164. Kaltsas G , Korbonits M , Heintz E , et al.   Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors . J Clin Endocrinol Metab . 2001;86:895–902
  165. Nocaudie-Calzada M , Huglo D , Carnaille B , et al.   Comparison of somatostatin analogue and metaiodobenzylguanidine scintigraphy for the detection of carcinoid tumours . Eur J Nucl Med . 1996;23:1448–1454
  166. Rufini V , Salvatori M , Saletnich I , et al.   Radiolabeled somatostatin analog scintigraphy in medullary thyroid carcinoma and carcinoid tumor . Q J Nucl Med . 1995;39(suppl 1 to no. 4):140–144
  167. Bomanji J , Mather S , Moyes J , et al.   A scintigraphic comparison of iodine-123-metaiodobenzylguanidine and a iodine-labeled somatostatin analog (tyr-3-octreotide) in metastatic carcinoid tumors . J Nucl Med . 1992;33:1121–1124
  168. Macfarlane D , Gonin J , Wieland D , et al.   Successful and unsuccessful approaches to imaging carcinoids (comparison of a radiolabelled tryptophan hydroxylase inhibitor with a tracer of biogenic amine uptake and storage, and a somatostatin analogue) . Eur J Nucl Med . 1996;23:131–140
  169. Ramage JK , Williams R , Buxton-Thomas M . Imaging secondary neuroendocrine tumours of the liver (comparison of I123 metaiodobenzylguanidine (MIBG) and In111-labelled octreotide (Octreoscan)) . QJM . 1996;89:539–542
  170. Isidori AM , Kaltsas G , Frajese V , et al.   Ocular metastases secondary to carcinoid tumors (The utility of imaging with [123I]Meta-Iodobenzylguanidine and [111In]DTPA Pentetreotide) . J Clin Endocrinol Metab . 2002;87:1627–1633
  171. Adams S , Baum RP , Hertel A , et al.   Metabolic (PET) and receptor (SPET) imaging of well-and less well-differentiated tumours (comparison with expression of the Ki-67 antigen) . Nucl Med Commun . 1998;19:641–647
  172. Eriksson B , Bergstrom M , Lija A , et al.   Positron emission tomography (PET) in neuroendocrine gastrointestinal tumors . Acta Oncol . 1993;32:189–196
  173. Hoegerle S , Altehoefer C , Ghanem N , et al.   Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors . Radiology . 2001;220:373–380
  174. Becherer A , Stabo M , Karanikas G , et al.   Imaging of advanced neuroendocrine tumours with 18F-DOPA PET . J Nucl Med . 2004;45:1161–1167
  175. Kowalski J , Henze M , Schuhmacher J , et al.   Evaluation of positron emission tomography imaging using [68Ga]-Dota-D-Phe(I)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors . Mol Imaging Biol . 2003;5:42–48
  176. Hofmann M , Boemer A , Krause T , et al.   Clinical application of Ga-68-DOTATOC in 132 patients with neuroendocrine tumors . (abstr) Eur J Nucl Med Mol Imaging . 2005;32:S53
  177. Öksüz MO , Aschoff P , Kemke B , et al.   Imaging of somatostatin-receptor expressing neuroendocrine tumours with 68Ga-DOTATOC-PET/CT versus 111In-DTPA-octreotide SPECT/CT . (abstr) Eur J Nucl Med Mol Imaging . 2005;32:S109
  178. Isidori AM , Kaltsas GA , Pozza C , et al.   The ectopic ACTH syndrome (clinical features, diagnosis, management and long-term follow-up) . J Clin Endocrinol Metab . 2006;91:371–377
  179. Ilias I , Torpy DJ , Pacak K , et al.   Cushing’s syndrome due to ectopic corticotropin secretion (twenty years’ experience at the National Institutes of Health) . J Clin Endocrinol Metab . 2005;90:4955–4962
  180. Tabarin A , Valli N , Chanson P , et al.   Usefulness of somatostatin receptor scintigraphy in patients with occult ectopic adrenocorticotropin syndrome . J Clin Endocrinol Metab . 1999;84:1193–1202
  181. Pacak K , Ilias I , Chen CC , et al.   The role of [18F]fluorodeoxyglucose positron emission tomography and [111In]-diethylenetriaminepentaacetate-D-Phe-pentetreotide scintigraphy in the localization of ectopic adrenocorticotropin-secreting tumors causing Cushing’s syndrome . J Clin Endocrinol Metab . 2004;89:2214–2221
  182. Roelants V , Delgrange E , Donckier J . Reply: Ectopic ACTH syndrome: a diagnostic challenge! . Clin Endocrinol . 2001;54:129–131
  183. Biering H , Pirlich M , Bauditz J , et al.   PET scan in occult ectopic ACTH syndrome a useful tool? . Clin Endocrinol . 2003;59:402–406
  184. Lairmore TC , Wells SA . Medullary carcinoma of the thyroid (current diagnosis and management) . Semin Surg Oncol . 1991;7:92–99
  185. Orlandi F , Caraci P , Mussa A , et al.   Treatment of medullary thyroid carcinoma (an update) . Endocr Relat Cancer . 2001;8:135–147
  186. Abdelmoumene N , Schlumberger M , Gardet P , et al.   Selective venous sampling catheterisation for localisation of persisting medullary thyroid carcinoma . Br J Cancer . 1994;69:1141–1144
  187. Kebebew E , Ituarte PH , Siperstein AE , et al.   Medullary thyroid carcinoma (clinical characteristics, treatment, prognostic factors, and a comparison of staging system) . Cancer . 2000;88:1139–1148
  188. Szavcsur P , Godeny M , Bajzik G , et al.   Angiography-proven liver metastases explain low efficacy of lymph node dissections in medullary thyroid cancer patients . Eur J Surg Oncol . 2005;31:183–190
  189. Kraeber-Bodere F , Bardet S , Hoefnagel CA , et al.   Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine-131-labeled bivalent hapten (preliminary results of a phase I/II clinical trial) . Clin Cancer Res . 1999;5:3190s–3198s
  190. Rufini V , Salvatori M , Garganese MC , et al.   Role of nuclear medicine in the diagnosis and therapy of medullary thyroid carcinoma . Rays . 2000;25:273–282
  191. Bodei L , Handkiewicz-Junak D , Grana C , et al.   Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas . Cancer Biother Radiopharm . 2004;19:65–71
  192. Baulieu JL , Guilloteau D , Delisle MJ , et al.   Radioiodinated meta-iodobenzylguanidine uptake in medullary thyroid cancer. A French cooperative study . Cancer . 1987;60:2189–2194
  193. Clarke SEM , Lazarus CR , Wraight P , et al.   Pentavalent 99m-Tc-DMSA, 131-I-MIBG, and 99m-Tc-MDP. An evaluation of three imaging techniques with medullary carcinoma of the thyroid . J Nucl Med . 1988;29:33–38
  194. Baudin E , Lumbroso J , Schlumberger M , et al.   Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma . J Nucl Med . 1996;37:912–916
  195. Dörr U , Sautter-Bihl ML , Bihl H . The contribution of somatostatin receptor scintigraphy and conventional imaging in medullary thyroid carcinoma . Semin Oncol . 1994;21(suppl 13):42–45
  196. Behr TM , Grayz S , Markus PM . Anticarcynoembrionic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma (are carcinoembryonic antigen and somatostatin receptor expression prognostic factors?) . Cancer . 1997;80:2436–2457
  197. Papotti M , Kumar U , Volante M , et al.   Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid . Clin Endocrinol . 2001;54:641–649
  198. Gao Z , Biersack HJ , Ezziddin TL , et al.   The role of combined imaging in metastatic medullary thyroid carcinoma (111In-DTPA-octreotide and 131I/123I-MIBG as predictors for radionuclide therapy) . J Cancer Res Clin Oncol . 2004;130:649–656
  199. Reubi JC , Chayvialle JA , Franc B , et al.   Somatostatin receptors and somatostatin content in medullary thyroid carcinomas . Lab Invest . 1991;64:567–573
  200. Behr TM , Becker W . Metabolic and receptor imaging of metastatic medullary thyroid cancer (does anti-CEA and somatostatin scintigraphy allow for prognostic predictions?) . Eur J Nucl Med . 1999;26:70–71
  201. Barbet J , Peltier P , Bardet S , et al.   Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA × anti-DTPA-indium bispecific antibody . J Nucl Med . 1998;39:1172–1178
  202. Siccardi G , Paganelli G , Pontiroli AE , et al.   In vivo imaging of chromogranin A positive endocrine tumors by three-step monoclonal antibody targeting . Eur J Nucl Med . 1996;23:1455–1459
  203. Parisella M , D’Alessandria C , van de Bossche B , et al.   99mTc-EDDA/HYNIC-TOC in the management of medullary thyroid carcinoma . Cancer Biother Radiopharm . 2004;19:211–217
  204. Diehl M , Risse JH , Brandt-Meinz K , et al.   Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer (results of a multicentric study) . Eur J Nucl Med . 2001;28:1671–1676
  205. Szakall S , Esik O , Bajzik G , et al.   18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma . J Nucl Med . 2002;43:66–71
  206. De Groot JW , Links TP , Jager PL , et al.   Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer . Ann Surg Oncol . 2004;11:786–794
  207. Khan N , Oriuchi N , Higuchi T , et al.   Review of fluorine-18-2-fluoro-2deoxy-D-glucose positron emission tomography (FDG-PET) in the follow-up of medullary and anaplastic thyroid carcinomas . Cancer Control . 2005;12:254–260
  208. Brandt-Mainz K , Muller SP , Gorges R , et al.   The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer . Eur J Nucl Med . 2000;27:490–496
  209. Gotthardt M , Battmann A , Höffken H , et al.   18F-FDG PET, somatostatin receptor scintigraphy, and CT in metastatic medullary thyroid carcinoma (a clinical study and an analysis of the literature) . Nucl Med Commun . 2004;25:439–443
  210. Baum RP , Schmücking M , Niesen A , et al.   Ga-68- DOTA-1-Nal3-Octreotide (DOTA-NOC) receptor PET/CT imaging for the diagnosis of neuroendocrine tumors and follow-up after peptide receptor radiotherapy (experience in 240 patients) . J Nucl Med . 2005;45(suppl 2):201P

PII: S0001-2998(06)00018-3

doi: 10.1053/j.semnuclmed.2006.03.007

Seminars in Nuclear Medicine
Volume 36, Issue 3 , Pages 228-247 , July 2006

Article Tools

* Image Usage & Resolution